MuLBSTA Score for Viral Pneumonia Mortality
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–5
- Moderate Risk6–11
- High Risk12–12
The MuLBSTA Score for Viral Pneumonia Mortality calculator is designed for bedside predicting 90-day mortality risk in patients with viral pneumonia using clinical and laboratory parameters to guide treatment decisions and resource allocation in clinical practice. The resulting score directly guides clinician decision-making regarding determining.
Clinical Guidelines & Evidence
Predicts 90-day mortality risk in patients with viral pneumonia using clinical and laboratory parameters to guide treatment decisions and resource allocation.
Clinical Indication
The MuLBSTA Score for Viral Pneumonia Mortality is indicated for bedside clinical practice to support Predicts 90-day mortality risk in patients with viral pneumonia using clinical and laboratory parameters to guide treatment decisions and resource allocation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with community-acquired pneumonia, COPD exacerbations, acute asthma, pulmonary embolism, or acute respiratory distress. Clinical application is indicated across Respiratory care units, emergency pulmonary triage, sleep clinics, and medical floors.
Limitations & Contraindications
Peripheral pulse oximetry loses reliability in hypoperfusion, severe vasoconstriction, methemoglobinemia, or carboxyhemoglobinemia.
Clinical Pearls & Action Plan
Synchronous evaluation of arterial blood gas (PaO2/FiO2), mechanics of breathing, and clinical trajectory guides respiratory failure management. Guideline pearl: Helps guide treatment intensity and resource allocation.
MuLBSTA Score = Multilobar infiltrates (5 points) + Lymphopenia (4 points) + Bacterial coinfection (4 points) + Smoking history (3 points) + Hypertension (2 points) + Age ≥60 years (2 points). Maximum score: 20 points, but practical maximum observed is 12 points.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| multilobar_infiltrates | string | Yes | Presence of multilobar infiltrates on chest imaging |
| lymphopenia | string | Yes | Lymphocyte count ≤0.8 × 10⁹/L |
| bacterial_coinfection | string | Yes | Presence of bacterial coinfection |
| smoking_history | string | Yes | Current or former smoking history |
| hypertension | string | Yes | History of hypertension |
| age_60_or_older | string | Yes | Age 60 years or older |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–5 | Low Risk | Low risk of 90-day mortality |
| 6–11 | Moderate Risk | Moderate risk of 90-day mortality |
| 12–12 | High Risk | High risk of 90-day mortality |
Evidence-Based References (EBM)
- Guo L, Wei D, Zhang X, Wu Y, Li Q, Zhou M, et al. Clinical Features Predicting Mortality Risk in Patients With Viral Pneumonia: The MuLBSTA Score. Front Microbiol. 2019;10:2752. doi: 10.3389/fmicb.2019.02752.DOI: 10.3389/fmicb.2019.02752
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7.DOI: 10.1016/S0140-6736(20)30211-7
- Fan G, Tu C, Zhou F, Liu Z, Wang Y, Song B, et al. Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. Eur Respir J. 2020;56(3):2002113. doi: 10.1183/13993003.02113-2020.DOI: 10.1183/13993003.02113-2020